Gilteritinib + Venetoclax + Azacitidine
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
Trial Timeline
Jan 31, 2023 → Jul 31, 2028
NCT ID
NCT05520567About Gilteritinib + Venetoclax + Azacitidine
Gilteritinib + Venetoclax + Azacitidine is a phase 1/2 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia (AML). The current trial status is active. This product is registered under clinical trial identifier NCT05520567. Target conditions include Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05520567 | Phase 1/2 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)